Advanced prostate cancer--a case for adjuvant differentiation therapy.
about
Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate CancerMolecular pathways and targets in prostate cancerDistinct phenotypes of human prostate cancer cells associate with different adaptation to hypoxia and pro-inflammatory gene expression.Multi-Drug Resistance ABC Transporter Inhibition Enhances Murine Ventral Prostate Stem/Progenitor Cell Differentiation.Context dependent regulatory patterns of the androgen receptor and androgen receptor target genesTLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells.CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9.DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation.Loss of SLCO1B3 drives taxane resistance in prostate cancerThe immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling.Enhancement of all-trans retinoic acid-induced differentiation by pH-sensitive nanoparticles for solid tumor cells.Harvesting Human Prostate Tissue Material and Culturing Primary Prostate Epithelial Cells.Conserved two-step regulatory mechanism of human epithelial differentiation.Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth.The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.
P2860
Q26742062-AC5F3A24-8A58-46CC-9DE6-1CC9C095AE8EQ34365632-E4BC1D3D-2D44-432F-878C-2C7F4CEE3424Q35163931-AEFC2221-AA28-4B35-81A9-0B26F5267551Q35585361-BF697558-87E4-440A-ACD9-EC8014553DDDQ36067956-AF61250F-AFFB-4046-A00B-C2660C664DA7Q36232040-E0E0FDCE-00BC-47DD-B85C-DDFE93B899F7Q36260616-C064855E-B039-49C0-8B36-E1EC0887545FQ37120262-485A3107-A575-45C6-B011-71B657E53415Q38642046-A846087E-AAA2-4A7C-A4FE-F2F59FE3683BQ38751260-90C2AE07-60BD-4AE1-9988-6023BAD5FE66Q38758652-406274B1-C92B-4F63-99EE-D7A1F73A9470Q39081865-01D0AD0B-7C5F-425A-BFF3-9AEF5BEEB20CQ39720960-B2EF84E3-9C0C-47E1-A5AC-1CD02ACB7EA7Q41892902-7B183D24-5224-433A-9E02-B60286E7546EQ47929908-26021F57-276C-46A8-A0D9-865A5E145ED4Q51321659-40035585-8E70-47A6-806D-875784900034
P2860
Advanced prostate cancer--a case for adjuvant differentiation therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Advanced prostate cancer--a case for adjuvant differentiation therapy.
@en
Advanced prostate cancer--a case for adjuvant differentiation therapy.
@nl
type
label
Advanced prostate cancer--a case for adjuvant differentiation therapy.
@en
Advanced prostate cancer--a case for adjuvant differentiation therapy.
@nl
prefLabel
Advanced prostate cancer--a case for adjuvant differentiation therapy.
@en
Advanced prostate cancer--a case for adjuvant differentiation therapy.
@nl
P2860
P356
P1476
Advanced prostate cancer--a case for adjuvant differentiation therapy.
@en
P2093
Davide Pellacani
Jayant K Rane
P2860
P2888
P304
P356
10.1038/NRUROL.2012.157
P407
P577
2012-08-14T00:00:00Z